The authors have evaluated etoposide as a single agent in the treatment of refractory multiple myeloma. There were two partial responses and nine patients with no disease progression in the group of 48 fully evaluable patients. This result suggests that etoposide as a single agent is not useful in heavily pretreated multiple myeloma. Whether etoposide is active earlier in the course of the disease needs further study.
